Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI

NCT02328443 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Healthy

Interventions

DRUG: Midazolam
DRUG: itraconazole
DRUG: rifampicin

Sponsor

Seoul National University Hospital